AC Immune
Adis Hoxha is an experienced finance professional currently serving as Manager of Financial Reporting and Controls at AC Immune since December 2022, where responsibilities include the preparation of IFRS financial statements for SEC filings and managing SOX compliance. In addition, Adis is a course instructor in IFRS and Swiss GAAP at Cursus Formation since November 2023. Prior to this role, experience includes serving as a Financial Consultant at Lambert & Forte, handling financial close activities for Bristol Myers Squibb/Celgene, and progressing from Junior to Assistant Manager in Audit at PwC Switzerland, focusing on financial audits and compliance. Educational qualifications include a Swiss Certified Public Accountant designation and a Master of Science in Accounting, Control, and Finance from HEC Lausanne.
Previous companies
This person is not in any offices
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.